VDRM (ViaDerma) YoY EBITDA Growth: 21.06% (As of Jun. 2012)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ViaDerma YoY EBITDA Growth?

ViaDerma VDRM YoY EBITDA Growth is 21.06% as of Jun. 2012.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. ViaDerma's YoY EBITDA Growth for the quarter that ended in Jun. 2012 was 21.06%.

ViaDerma's EBITDA per Share for the three months ended in Jun. 2012 was $17.12.

ViaDerma YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for ViaDerma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViaDerma YoY EBITDA Growth Chart

ViaDerma Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11
YoY EBITDA Growth
0.00 657.40 -28.01 33.30 -26.48

ViaDerma Quarterly Data
Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.28 -35.33 -26.10 -6.88 21.06

ViaDerma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

ViaDerma's YoY EBITDA Growth for the fiscal year that ended in Dec. 2011 is calculated as:

YoY EBITDA Growth (A: Dec. 2011 )
=(EBITDA per Share (A: Dec. 2011 )-EBITDA per Share (A: Dec. 2010 ))/ | EBITDA per Share (A: Dec. 2010 ) |
=(50.051-68.08)/ | 68.08 |
=-26.48 %

ViaDerma's YoY EBITDA Growth for the quarter that ended in Jun. 2012 is calculated as:

YoY EBITDA Growth (Q: Jun. 2012 )
=(EBITDA per Share (Q: Jun. 2012 )-EBITDA per Share (Q: Jun. 2011 )) / | EBITDA per Share (Q: Jun. 2011 )) |
=(17.117-14.139)/ | 14.139 |
=21.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 21.06% mean?
ViaDerma (VDRM) has a YoY EBITDA Growth of 21.06% as of Jun. 2012. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for ViaDerma and its competitors.
Is ViaDerma's YoY EBITDA Growth too high?
ViaDerma's current YoY EBITDA Growth is 21.06%.
How does ViaDerma's YoY EBITDA Growth compare to AOLS and RDGL?
ViaDerma's YoY EBITDA Growth of 21.06% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for ViaDerma and its competitors. ViaDerma's current YoY EBITDA Growth is 21.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViaDerma stock overvalued right now?
ViaDerma (VDRM) has a current YoY EBITDA Growth of 21.06%. The current YoY EBITDA Growth is 21.06%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For ViaDerma (VDRM), the current YoY EBITDA Growth is 21.06% as of Jun. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ViaDerma Business Description

Address 4640 Admiralty Way, Suite 500, Marina Del Rey, CA, USA, 90292
ViaDerma Inc is a specialty pharmaceutical company focused to bring new products to market through research and development. It is engaged in the business of manufacturing and sales of pharmaceuticals, and specifically topical antibiotics and pain management in the United States of America. Its sells under the brand name Vitastem. The Company also has products in development in the fields; anti-aging skin care, pain management, hair-loss, and toenail fungus.